Thought Leader Insight & Analysis: Alzheimer's Disease - Market Research Reports

Welcome - Home - Register - Login - Help/FAQ - 0 items

Search
Enter keywords, a title or
a report id number below.

Advanced


	Select a currency for use throughout the site

Viewing report

Order by Fax
Printer Friendly
PDF Brochure
Send to Friend
Enquire before Buying

| More

Hard Copy
Enterprisewide

Thought Leader Insight & Analysis: Alzheimer's Disease
Medpredict, Jan 2008



		Description


	Table of Contents



		Products Mentioned



		Enquire before Buying



		Send to a Friend

Executive Summary

Bulleted Highlights
- Diagnostics
- Drugs

Key Findings
Diagnostics / Imaging / Biomarkers
- PIB (General Electric)
- Stable Label (Bateman / Holtzman)
- 18F-AV-1/ZK (Bayer-Schering / Avid Radiopharmaceuticals)
- SA101 / SA102 (Satoris)

Obituaries
- Alzhemed (tramiprosate; NC758; Neurochem)
- Xaprila (xaliproden); Sanofi-Aventis

Cholinesterase Inhibitors
- Exelon (rivastigmine; Novartis)
- Razadyne ER (galantamine; J&J)
- Debio 9902 SR (Debio)
- NGX267; M1 Receptor Agonist (TorreyPines)

NMDA Antagonists
- Namenda / Axura / Ebixa (memantine; Forest / Merz / Lundbeck / Daiichi-Sankyo)
- Dimebon (dimebolin; Medivation)
- NP-0361 (Neuropharma / Zeltia)

alpha-7 nicotinic acetylcholine agonist
- ABT-089 (Abbott)
- AZD-0328 (AstraZeneca)
- R-4996 / MEM-63908 (Roche / Memory)
- EVP-6124 (EnVivo / Bayer-Schering)

Immunotherapies
Passive
- Gammagard (IVIG; Baxter)
- Bapineuzumab (AAB-001); Elan/Wyeth
- LY2062430; Lilly
- PF-4360365 (RN1219; Pfizer)
- AAB-002 (Elan / Wyeth)
- ACU-5A5 Mab (Merck)
- R-1450 (Roche / Morphosys)
- ACI-01-Ab7 (AC Immune / Genentech)
- BAN-2401 (Eisai / BioArctic)
- Novartis

Active Immunization
- CAD-106; Novartis
- V-950; Merck
- ACC-001 (Elan / Wyeth)
- Affitope AD01 (Affiris)
- ACI-24 (AC Immune)
- Boehringer-Ingelheim / Ablynx
- PADRE (Lundbeck / Pharmexa)

y-Secretase Inhibitors, ?-Secretase Modulators
- Flurizan (tarenflurbil; R-flurbiprofen; Myriad)
- LY-450139 ( Lilly / Elan)
- GSI-953; Wyeth
- MK-0752; Merck
- Schering-Plough
- Elan
- BMS
- TorreyPines
- Cellzome / J&J

ß-Secretase Inhibitors
- CTS-21166; CoMentis
- Preclinical BACE Programs

Anti-TNF
- Enbrel (etanercept; Wyeth/Amgen)

Insulin Related
- Avandia (rosiglitazone); GSK
- TTP-488 (RAGE Inhibitor); TransTec / Pfizer
- NGX-96992; TorreyPines
- Insulin Degrading Enzyme (Wyeth)
- Ketasyn (AC-1202; Accera)
- SRT-501; NCE-1; NCE-2 (Sirtris)

Tau / GSK3 Inhibitors
- NP031112 (Neuropharma)
- AstraZeneca

Coagulation Cascade
- PAI-1 Antagonist (Wyeth)

Metal Chelators
- PBT2; Prana

Statins
- Lipitor (atorvastatin; Pfizer)
- Zocor (simvastatin; Merck)

Hormonal
- Evista (raloxifene); Lilly

5-HT / GABA
- lecozotan / lecozotan SR (Wyeth)80
- PRX-03140 (Epix / GSK)
- MK-0249
- 742457 (SB-742457; GSK)

Other Anti-Amyloid
- ELND005 (scyllo-inositol; AZD-103; Elan / Transition Therapeutics)
- caprospinol (SP-233; Samaritan)

Thought-Leader Discussions
- Interview CNS01967
- Interview CNS01968
- Interview CNS01969
- Interview CNS01970
- Interview CNS01971
- Interview CNS01972
- Interview CNS01973

Customers who bought this item also bought

Wyeth

Alzheimer Disease - New Drugs, Markets and Companies

Central Nervous System Alzheimer Disease

Analysis of Wyeth

Central Nervous System - Alzheimer Disease Drug Pipeline Report

Emerging Drug Targets in Alzheimer's Disease

Bapineuzumab Phase 2 Clinical Trial Results Call - Wyeth,Elan Corp. Plc, - Earnings Transcript

Bapineuzumab Phase 2 Clinical Trial Results Call - Wyeth,Elan Corp. Plc, - Earnings Transcript

Small Molecule Kinase Inhibitors - Global Strategic Business Report

Acquisition of Wyeth by Pfizer, Inc Call - - Earnings Transcript

Acquisition of Wyeth by Pfizer, Inc Call - - Earnings Transcript

CNS Drug Discoveries: Alzheimer's Disease Chapter

Top of page